77:
179:
36:
226:
425:
Disease-specific survival rate refers to "the percentage of people in a study or treatment group who have not died from a specific disease in a defined period of time. The time period usually begins at the time of diagnosis or at the start of treatment and ends at the time of death. Patients who died
308:
in certain disease conditions, and can be used for the assessment of standards of therapy. The survival period is usually reckoned from date of diagnosis or start of treatment. Survival rates are based on the population as a whole and cannot be applied directly to an individual. There are various
416:
is calculated by dividing the overall survival after diagnosis of a disease by the survival as observed in a similar population that was not diagnosed with that disease. A similar population is composed of individuals with at least age and gender similar to those diagnosed with the disease.
398:
Relative survival has the advantage that it does not depend on accuracy of the reported cause of death; cause specific survival has the advantage that it does not depend on the ability to find a similar population of people without the disease.
763:
Michaeli DT, Michaeli T (2022). "Overall
Survival, Progression-Free Survival, and Tumor Response Benefit Supporting Initial US Food and Drug Administration Approval and Indication Extension of New Cancer Drugs, 2003-2021".
678:
Fojo T, Mailankody S, Lo A (2014). "Unintended
Consequences of Expensive Cancer Therapeutics—The Pursuit of Marginal Indications and a Me-Too Mentality That Stifles Innovation and Creativity: The John Conley Lecture".
437:
survival, or "median overall survival" is also commonly used to express survival rates. This is the amount of time after which 50% of the patients have died and 50% have survived. In ongoing settings such as
363:
Sometimes the overall survival is reported as a death rate (%) without specifying the period the % applies to (possibly one year) or the period it is averaged over (possibly five years), e.g.
192:
tone and sophistication of existing content are non-encyclopedic, and alongside complete lack of citations (disallowing content verification), article is untrustworthy apart from expert attention.
714:
Ladanie A, Schmitt AM, Speich B, Naudet F, Agarwal A, Pereira TV, Sclafani F, Herbrand AK, Briel M, Martin-Liberal J, Schmid T, Ewald H, Ioannidis JP, Bucher HC, Kasenda B, Hemkens LG (2020).
352:. Doctors often use mean overall survival rates to estimate the patient's prognosis. This is often expressed over standard time periods, like one, five, and ten years. For example,
544:
538:
304:. It is the proportion of people in a study or treatment group still alive at a given period of time after diagnosis. It is a method of describing
524:
is detected). Progression can be categorized as local progression, regional progression, locoregional progression, and metastatic progression.
461:
improve overall survival by a median of 2 to 3 months depending on the sample and analyzed time period: 2.1 months, 2.4 months, 2.8 months.
284:
265:
160:
63:
813:
381:, which filters out the effect of mortality from other causes than the disease. The two main ways to calculate net survival are
716:"Clinical Trial Evidence Supporting US Food and Drug Administration Approval of Novel Cancer Therapies Between 2000 and 2016"
200:
98:
94:
49:
141:
113:
458:
454:
310:
818:
120:
457:
to evaluate the effectiveness of a novel cancer treatment. Studies find that new cancer drugs approved by the U.S.
247:
236:
533:
509:
487:
127:
640:
565:
475:
470:
87:
109:
823:
512:(PFS) (the period after treatment when disease remains stable, that is, does not progress), and the
789:
243:
195:
55:
442:, the median has the advantage that it can be calculated once 50% of subjects have reached the
828:
781:
745:
696:
623:
447:
443:
413:
408:
383:
357:
333:
301:
773:
735:
727:
688:
613:
603:
134:
493:
353:
314:
377:
When someone is interested in how survival is affected by the disease, there is also the
740:
731:
715:
618:
591:
501:
439:
426:
from causes other than the disease being studied are not counted in this measurement."
341:
807:
793:
608:
366:
Obinutuzumab: A Novel Anti-CD20 Monoclonal
Antibody for Chronic Lymphocytic Leukemia
337:
508:(DFS) (the period after curative treatment when no disease can be detected), the
652:
336:) can die directly from that disease or from an unrelated cause (for example, a
76:
17:
364:
692:
521:
482:
Disease-free survival, progression-free survival, and metastasis-free survival
305:
785:
749:
700:
627:
777:
329:
325:
497:
434:
592:"Cancer Survival: An Overview of Measures, Uses, and Interpretation"
496:, various types of survival rate can be relevant, depending on the
450:
can only be done after all subjects have reached the endpoint.
309:
types of survival rates (discussed below). They often serve as
219:
172:
70:
29:
453:
The median overall survival is frequently used by the U.S.
356:
has a much higher one-year overall survival rate than
421:
Cause-specific survival and disease-specific survival
246:. Please help to ensure that disputed statements are
545:
Surveillance, Epidemiology, and End
Results database
590:Mariotto AB, Noone AM, Howlader N (November 2014).
101:. Unsourced material may be challenged and removed.
478:measures survival at five years after diagnosis.
641:Definition : disease-specific survival rate
8:
539:Response Evaluation Criteria in Solid Tumors
64:Learn how and when to remove these messages
188:needs attention from an expert in Medicine
739:
617:
607:
285:Learn how and when to remove this message
266:Learn how and when to remove this message
161:Learn how and when to remove this message
659:. National Cancere Institute. 2011-02-02
446:of the trial, whereas calculation of an
242:Relevant discussion may be found on the
557:
203:may be able to help recruit an expert.
344:is not specified, this is called the
7:
99:adding citations to reliable sources
360:, and thus has a better prognosis.
732:10.1001/jamanetworkopen.2020.24406
25:
45:This article has multiple issues.
566:"NCI Dictionary of Cancer Terms"
518:distant metastasis–free survival
313:and should not be confused with
224:
177:
75:
34:
681:JAMA Otolaryngol Head Neck Surg
86:needs additional citations for
53:or discuss these issues on the
657:NCI Dictionary of Cancer Terms
1:
609:10.1093/jncimonographs/lgu024
766:Journal of Clinical Oncology
459:Food and Drug Administration
455:Food and Drug Administration
311:endpoints of clinical trials
190:. The specific problem is:
27:Medical analysis of disease
845:
485:
468:
406:
693:10.1001/jamaoto.2014.1570
653:"median overall survival"
570:National Cancer Institute
534:Progression-free survival
520:(DMFS) (the period until
510:progression-free survival
488:Progression-free survival
393:disease-specific survival
514:metastasis-free survival
814:Demographics indicators
476:Five-year survival rate
471:Five-year survival rate
389:cause-specific survival
317:, a population metric.
350:observed survival rate
506:disease-free survival
346:overall survival rate
778:10.1200/JCO.22.00535
504:. These include the
340:). When the precise
235:factual accuracy is
201:WikiProject Medicine
95:improve this article
186:This documentation
819:Statistical ratios
465:Five-year survival
772:(35): 4095–4106.
687:(12): 1225–1236.
448:arithmetical mean
444:clinical endpoint
414:Relative survival
409:Relative survival
403:Relative survival
384:relative survival
379:net survival rate
373:Net survival rate
358:pancreatic cancer
334:colorectal cancer
302:survival analysis
295:
294:
287:
276:
275:
268:
218:
217:
171:
170:
163:
145:
68:
16:(Redirected from
836:
798:
797:
760:
754:
753:
743:
726:(11): e2024406.
711:
705:
704:
675:
669:
668:
666:
664:
649:
643:
638:
632:
631:
621:
611:
587:
581:
580:
578:
577:
562:
321:Overall survival
290:
283:
271:
264:
260:
257:
251:
248:reliably sourced
228:
227:
220:
213:
210:
204:
181:
180:
173:
166:
159:
155:
152:
146:
144:
103:
79:
71:
60:
38:
37:
30:
21:
18:Overall survival
844:
843:
839:
838:
837:
835:
834:
833:
804:
803:
802:
801:
762:
761:
757:
713:
712:
708:
677:
676:
672:
662:
660:
651:
650:
646:
639:
635:
602:(49): 145–186.
596:JNCI Monographs
589:
588:
584:
575:
573:
564:
563:
559:
554:
530:
494:cancer research
490:
484:
473:
467:
440:clinical trials
432:
430:Median survival
423:
411:
405:
375:
354:prostate cancer
328:with a certain
323:
315:mortality rates
291:
280:
279:
278:
272:
261:
255:
252:
241:
233:This article's
229:
225:
214:
208:
205:
199:
182:
178:
167:
156:
150:
147:
110:"Survival rate"
104:
102:
92:
80:
39:
35:
28:
23:
22:
15:
12:
11:
5:
842:
840:
832:
831:
826:
821:
816:
806:
805:
800:
799:
755:
720:JAMA Netw Open
706:
670:
644:
633:
582:
556:
555:
553:
550:
549:
548:
542:
536:
529:
526:
486:Main article:
483:
480:
469:Main article:
466:
463:
431:
428:
422:
419:
407:Main article:
404:
401:
374:
371:
342:cause of death
332:(for example,
322:
319:
293:
292:
274:
273:
232:
230:
223:
216:
215:
185:
183:
176:
169:
168:
83:
81:
74:
69:
43:
42:
40:
33:
26:
24:
14:
13:
10:
9:
6:
4:
3:
2:
841:
830:
827:
825:
822:
820:
817:
815:
812:
811:
809:
795:
791:
787:
783:
779:
775:
771:
767:
759:
756:
751:
747:
742:
737:
733:
729:
725:
721:
717:
710:
707:
702:
698:
694:
690:
686:
682:
674:
671:
658:
654:
648:
645:
642:
637:
634:
629:
625:
620:
615:
610:
605:
601:
597:
593:
586:
583:
571:
567:
561:
558:
551:
546:
543:
540:
537:
535:
532:
531:
527:
525:
523:
519:
515:
511:
507:
503:
499:
495:
489:
481:
479:
477:
472:
464:
462:
460:
456:
451:
449:
445:
441:
436:
429:
427:
420:
418:
415:
410:
402:
400:
396:
394:
390:
386:
385:
380:
372:
370:
368:
367:
361:
359:
355:
351:
347:
343:
339:
335:
331:
327:
320:
318:
316:
312:
307:
303:
300:is a part of
299:
298:Survival rate
289:
286:
270:
267:
259:
249:
245:
239:
238:
231:
222:
221:
212:
202:
197:
193:
189:
184:
175:
174:
165:
162:
154:
143:
140:
136:
133:
129:
126:
122:
119:
115:
112: –
111:
107:
106:Find sources:
100:
96:
90:
89:
84:This article
82:
78:
73:
72:
67:
65:
58:
57:
52:
51:
46:
41:
32:
31:
19:
824:Epidemiology
769:
765:
758:
723:
719:
709:
684:
680:
673:
661:. Retrieved
656:
647:
636:
599:
595:
585:
574:. Retrieved
572:. 2011-02-02
569:
560:
517:
513:
505:
491:
474:
452:
433:
424:
412:
397:
392:
388:
382:
378:
376:
365:
362:
349:
345:
338:car accident
324:
297:
296:
281:
262:
253:
234:
206:
198:for details.
191:
187:
157:
148:
138:
131:
124:
117:
105:
93:Please help
88:verification
85:
61:
54:
48:
47:Please help
44:
808:Categories
663:4 December
576:2016-04-22
552:References
522:metastasis
121:newspapers
50:improve it
794:251317641
516:(MFS) or
500:type and
306:prognosis
244:talk page
196:talk page
56:talk page
829:Survival
786:35921606
750:33170262
701:25068501
628:25417231
541:(RECIST)
528:See also
326:Patients
256:May 2014
237:disputed
209:May 2014
194:See the
151:May 2014
741:7656288
619:4829054
330:disease
135:scholar
792:
784:
748:
738:
699:
626:
616:
547:(SEER)
498:cancer
435:Median
277:.
137:
130:
123:
116:
108:
790:S2CID
502:stage
142:JSTOR
128:books
782:PMID
746:PMID
697:PMID
665:2014
624:PMID
600:2014
387:and
114:news
774:doi
736:PMC
728:doi
689:doi
685:140
614:PMC
604:doi
492:In
391:or
348:or
97:by
810::
788:.
780:.
770:40
768:.
744:.
734:.
722:.
718:.
695:.
683:.
655:.
622:.
612:.
598:.
594:.
568:.
395:.
369:.
59:.
796:.
776::
752:.
730::
724:3
703:.
691::
667:.
630:.
606::
579:.
288:)
282:(
269:)
263:(
258:)
254:(
250:.
240:.
211:)
207:(
164:)
158:(
153:)
149:(
139:·
132:·
125:·
118:·
91:.
66:)
62:(
20:)
Text is available under the Creative Commons Attribution-ShareAlike License. Additional terms may apply.
